Harvest Fund Management Co. Ltd Purchases New Shares in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Harvest Fund Management Co. Ltd purchased a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the first quarter, HoldingsChannel reports. The fund purchased 2,500 shares of the company’s stock, valued at approximately $227,000.

A number of other hedge funds also recently bought and sold shares of the business. Banque Cantonale Vaudoise bought a new position in BioNTech during the first quarter valued at $36,000. Goodman Advisory Group LLC bought a new position in BioNTech during the first quarter valued at $105,000. Whittier Trust Co. increased its position in BioNTech by 3,846.2% during the first quarter. Whittier Trust Co. now owns 2,052 shares of the company’s stock valued at $187,000 after acquiring an additional 2,000 shares during the last quarter. Tower Research Capital LLC TRC increased its position in BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company’s stock valued at $214,000 after acquiring an additional 713 shares during the last quarter. Finally, Probity Advisors Inc. increased its position in BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BNTX shares. Morgan Stanley upped their price target on shares of BioNTech from $132.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 10th. The Goldman Sachs Group started coverage on shares of BioNTech in a report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 price target on the stock. Citigroup restated a “buy” rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. HC Wainwright restated a “buy” rating and issued a $138.00 price target on shares of BioNTech in a report on Wednesday, June 25th. Finally, Bank of America cut their price target on shares of BioNTech from $127.00 to $126.00 and set a “buy” rating on the stock in a report on Wednesday, July 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $136.58.

BioNTech Stock Down 1.3%

NASDAQ:BNTX opened at $110.05 on Thursday. BioNTech SE Sponsored ADR has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a 50-day moving average of $107.77 and a 200 day moving average of $106.35. The firm has a market cap of $26.45 billion, a PE ratio of -32.37 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.